Foghorn goes quiet on non-selective project

Hopes for Foghorn’s SMARCA2/4 inhibitor FHD-286 were already low after discontinuation in uveal melanoma, and on Monday the company ditched the asset entirely. Foghorn said FHD-286 hadn’t met the hoped-for efficacy threshold in a phase 1 relapsed/refractory AML trial, where it was being tested alongside decitabine; the group will look for partnerships but the project is effectively dead in the water. The focus now shifts to LY4050784, a Lilly-partnered oral selective SMARCA2 inhibitor that this year started phase 1 in SMARCA4-mutated solid tumours – with a particular focus on NSCLC, where nearly 10% of patients have SMARCA4 alterations, according to Foghorn. The group also has a SMARCA2 degrader in preclinical development; however, the jury’s still out on this approach, with Prelude’s intravenous degrader PRT3789 producing just three responses among 26 NSCLC and oesophageal cancer in a phase 1 trial presented at ESMO. Prelude also has a similarly-acting oral asset, PRT7732, in the clinic. Foghorn, meanwhile, is developing several undisclosed projects in partnership with Lilly, as well as wholly owned preclinical degraders of CBP and the related EP300, and ARID1B: in the latter Foghorn is the only active company, according to OncologyPipeline. Foghorn dipped 5% on Monday, while Prelude rose 6%. 

Foghorn’s pipeline

Source: OncologyPipeline & company presentation.